EGFR and lung adenocarcinoma: In the Phase III First-SIGNAL study, high EGFR mutation positivity in plasma was associated with significantly shorter survival in gefitinib-treated patients with lung adenocarcinoma vs low EGFR mutation positivity (P=0.03) (Lee et al, 2011).